These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38809459)

  • 1. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
    Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
    Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.
    Veen T; Kanani A; Lea D; Søreide K
    Cancer Immunol Immunother; 2023 Oct; 72(10):3135-3147. PubMed ID: 37528319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.
    Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z
    Front Immunol; 2022; 13():1001444. PubMed ID: 36159842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
    Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ
    JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
    Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
    JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
    Lin KX; Istl AC; Quan D; Skaro A; Tang E; Zheng X
    Cancer Immunol Immunother; 2023 Dec; 72(12):3875-3893. PubMed ID: 37831146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic impact of programmed death - 1 in the treatment of colorectal cancer.
    Sangani PS; Yazdani S; Khalili-Tanha G; Ghorbani E; Al-Hayawi IS; Fiuji H; Khazaei M; Hassanian SM; Kiani M; Ghayour-Mobarhan M; Ferns GA; Nazari E; Avan A
    Pathol Res Pract; 2024 Jul; 259():155345. PubMed ID: 38805760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
    Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
    Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis.
    Li Y; Du Y; Xue C; Wu P; Du N; Zhu G; Xu H; Zhu Z
    BMC Gastroenterol; 2022 Oct; 22(1):431. PubMed ID: 36217119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
    Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer.
    Hyung J; Cho EJ; Kim J; Kim JH; Kim JE; Hong YS; Kim TW; Sung CO; Kim SY
    Cancer Res Treat; 2022 Oct; 54(4):1175-1190. PubMed ID: 35038827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
    Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
    BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
    Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
    World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.
    Cai L; Chen A; Tang D
    Immunology; 2024 Mar; ():. PubMed ID: 38517066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery.
    Shadbad MA; Asadzadeh Z; Derakhshani A; Hosseinkhani N; Mokhtarzadeh A; Baghbanzadeh A; Hajiasgharzadeh K; Brunetti O; Argentiero A; Racanelli V; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Nov; 143():112213. PubMed ID: 34560556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.